PATIENT-HOTLINE

Patients and relatives can contact short at this point of contact for questions, suggestions and criticism.

+49 (0) 800/ 660 68 00

We are there for you at the following times

Monday to Friday from 8.00 am to 6.00 pm

Contact

RINECKER PROTON THERAPY CENTER
Franz-von-Rinecker Straße (main entrance)

Schäftlarnstraße 133 (postal address)

81371 München

Do you have any questions?
+49 (0) 800/ 660 68 00

About us

The RINECKER PROTON THERAPY CENTER

The RPTC, located in Munich, is the first fully certified European proton radiation center which provides a complete hospital setting for the treatment of cancer tumors.

Our innovative therapeutic procedure involves the use of high-energy proton beams for the treatment of cancer. A key characteristic of these proton beams is that protons facilitate the three-dimensional targeting of tumours; this capability is not available with the x-rays used in conventional radiation therapy. Therefore, highly effective dosages can be delivered to the tumour while the side effects of radiation are reduced by minimizing any trauma to the surrounding healthy tissue.

Questions? +49 (0) 800/ 660 68 00

Clinical experience

Clinical experience

Proton therapy was first proposed for cancer by the nuclear physicist Robert R. Wilson in the late 1940s. Since the 1950s, approximately more than 70,000 cancer patients throughout the world have been successfully treated with protons–-usually in physics research laboratories, where treatment options have generally been limited to specific tumor types and relatively few patients per year.

It is beneficial for patients that the local dose effect in conventional X-ray radiation can be applied to proton radiation with a factor of 1:1,1. The biological mechanism of effect of both types of radiation is essentially the same: separating electrons from a molecule – “ionization.” This leads, via intermediate stages, to damage of the nucleus and cell death during the next division of the cell.

Knowledge with regard to dose-effect relationships has been gained from 100 years of radiation therapy. The critical advantage of protons – especially with the scanning method used at the RPTC- is the outstanding dose distribution: concentration in the tumor – protection of healthy tissue

Outside the USA and Japan, there are very few proton centers that offer a complete hospital setting, treatments for all areas of the body, and the ability to serve large numbers of patients.
Centers that have been able to amass a great deal of experience are at Loma Linda University (near Los Angeles), and in Boston at the Massachusetts General Hospital of Harvard University, as well as at the renowned MD Anderson Cancer Center in Houston, Texas. In addition to the RPTC in Munich, the Hahn-Meitner-Institut (HMI) in Berlin is another center in Germany, although it only treats ocular tumors.
 
Except for the RPTC and the research institutes Paul-Scherrer (PSI) in Villingen/Switzerland and the ‘Gesellschaft für Schwerionenforschung (GSI) in Darmstadt’, all the systems in Europe operate with the older scattering method using templates.
 
Click here to read more about the advantages and options associated with the scanning procedure used at RPTC.

Particle facilities Japan and USA in operation March 2010

Center Country Particle type Maximum Energy Operating since
Loma Linda USA Proton 250 MeV 1990
HIMAC, Chiba JP Carbon ion 800 MeV/u 1994
NCC, Kashiwa JP Proton 235 MeV 1998
HIBMC,Hyogo JP Proton 230 MeV 2001
PMRC, Tsukuba JP Proton 250 MeV 2001
NPTC, MGH, Boston USA Proton 235 MeV 2001
Shizuoka JP Proton 235 MeV 2003
MPRI, Bloomington USA Proton 200 MeV 2004
MD Anderson, Houston USA Proton (scanning) 250 MeV 2006
FPTI, Jacksonville USA Proton 230 MeV 2006
ProCure, Oklahoma City USA Proton 230 MeV 2009
Upenn, Philadelphia USA Proton 230 MeV 2010

Particle facilities worldwide in operation till end of 2010

Center Country Particle type Maximum Energy Operating since
Loma Linda USA Proton 250 MeV 1990
HIMAC, Chiba JP Carbon ion 800 MeV/u 1994
NCC, Kashiwa JP Proton 235 MeV 1998
HIBMC, Hyogo JP Proton 230 MeV 2001
PMRC, Tsukuba JP Proton 250 MeV 2001
NPTC, MGH, Boston USA Proton 235 MeV 2001
Shizuoka JP Proton 235 MeV 2003
MPRI, Bloomington USA Proton 200 MeV 2004
WPTC, Zibo CN Proton 230 MeV 2004
MD Anderson, Houston USA Proton (scanning) 250 MeV 2006
FPTI, Jacksonville USA Proton 230 MeV 2006
NCC, IIsan KR Proton 230 MeV 2007
ProCure, Oklahoma City USA Proton 230 MeV 2009
RPTC München D Proton (scanning) 250 MeV 2009
HIT, Heidelberg D Proton, Carbon ion 430 MeV/u 2009
Upenn, Philadelphia USA Proton 230 MeV 2010
CNAO, Pavia IT Proton, Carbon ion 430 MeV/u 2010
WPE, Essen D Proton 230 MeV 2010
CPO, Orsay FR Proton 230 MeV 2010
PTC, Marburg D Proton, Carbon ion 430 MeV/u 2010
Gunma, Maebashi JP Carbon ion 400 MeV/u 2010
HUPBTC, Hampton USA Proton 230 MeV 2010
SJFH, Peking CN Proton 230 MeV 2010

Particle facilites worldwide planning / construction in progress March 2010

Center Country Particle type Maximum Energy Operating since
PTC Czech CZ Proton 250 MeV 2013
Med-Austron, Wiener Neustadt AT Proton, Carbon ion 400 MeV/u 2013
Trento IT Proton 230 MeV 2011
Northern Illinois, Chicago USA Proton 250 MeV 2011
NRoCK, Kiel D Proton, Carbon ion 430 MeV/u 2012
Chang Gun, Taipei TW Proton 235 MeV 2011
PCPTC, Chicago USA Proton 230 MeV 2011
PMHPTC, Protvino RU Proton 250 MeV 2010
Skandion, Uppsala SE Proton 250 MeV 2013
HollandPTC, Randstadt NL Proton 250 MeV 2012
ProCure Michigan, Detroit USA Proton 230 MeV 2013+
ProCure Florida USA Proton 230 MeV 2013+
ProCure Washington, Seattle USA Proton 230 MeV 2013+
ProCure New Jersey, Somerset USA Proton 230 MeV 2013+
iThemba Labs (Ausbau) Südafrika Proton 230 MeV 2013+
PSI CH Proton 72 MeV 1984
Copyright © 2017 Pro Health AG